Citigroup analyst Andrew Kaplowitz maintains 3M (NYSE:MMM) with a Neutral and raises the price target from $117 to $126.
Sanofi/Regeneron’s Blockbuster Prescription Drug Dupixent Shows Additional Promise In Chronic Lung Disorder
Regeneron Pharmaceuticals Inc (NASDAQ: REGN) and Sanofi SA (NASDAQ: SNY) announced the second Dupixent (dupilumab) Phase 3 chronic obstructive pulmonary disease (COPD) trial (NOTUS) showed that Dupixent&nb